ClinicalTrials.gg
CompletedNCT06169995Updated Dec 29, 2023

A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy

A Phase 4 interventional study of Remimazolam Tosilate in Sedation in the Upper Gastrointestinal Endoscopy, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-29.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in Upper Gastrointestinal Endoscopy

02

Conditions studied

  • Sedation in the Upper Gastrointestinal Endoscopy
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients or their guardians are able to provide a written
  2. participants undergo upper gastrointestinal endoscopy
  3. ≥18 years old, male or female
  4. 18 kg/m2≤bmi≤30kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Subjects to be intubated (including laryngeal mask placement);
  2. Complex endoscopic diagnosis and treatment operations are required;
  3. Severe cardiovascular disease within 6 months prior to signing the ICF;
  4. Heart rate \< 50 beats/min during screening period;
  5. Subjects with poor blood pressure control during screening;
  6. Severe arrhythmias or heart disease; the circulatory system is unstable;
  7. Subjects with a history of severe cardiovascular disease, or cerebrovascular disease, or neurological disease, or mental illness
  8. Subjects with a history of drug abuse;
  9. Abnormal values of the laboratory examination;
  10. Allergic to relevant drugs ingredient or component;
  11. Pregnant or nursing women;
  12. Subjects who has participated in clinical trials of other interventions recently;
  13. Other conditions deemed unsuitable to be included.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Remimazolam Tosilate for Injection

    Drug: Remimazolam Tosilate

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage(%) of paticipants who experienced successful sedation in Upper Gastrointestinal Endoscopy

    Time frame: on Day1

Secondary outcomes

  1. Percentage of subjects receiving supplemental dose for sedation

    Time frame: on Day1

  2. The number of supplemental doses of the research drug

    Time frame: on Day1

  3. Wake-up time.

    Time frame: on Day1

  4. Incidence of sedation hypotension.

    Time frame: on Day1

  5. Incidence of respiratory depression

    Time frame: on Day1

07

Study locations

2 sites
  • The Affiliated Hospital Of Guizhou Medical University
    Guiyang, Guizhou 550000, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Dec 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 14, 2023
StartActual
Dec 11, 2023
Primary completionActual
Dec 15, 2023
CompletionActual
Dec 16, 2023
Last update
Dec 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169995
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Dec 11, 2023
Primary completion
Dec 15, 2023
Completion
Dec 16, 2023
Last update
Dec 29, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion